Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | FADS1 | O60427 | 6/20 | 0.56 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12325176 | 0.75 | TRPA1 (0.55) | TRPA1FADS1GRM4ADRA2AAURKA | |
| SCHEMBL4783454 | 0.72 | FADS1 (1.00) | TRPA1FADS1GRM4 | |
| SCHEMBL802545 | 0.71 | FADS1 (0.47) | TRPA1FADS1GRM4ADRA2A | |
| SCHEMBL18274872 | 0.71 | TRPA1 (0.57) | TRPA1FADS1GRM4ADRA2AAURKA | |
| SCHEMBL857502 | 0.71 | NPC1 (0.63) | NPC1 | |
| SCHEMBL29882003 | 0.71 | TRPA1 (0.75) | TRPA1FADS1GRM4ADRA2AAURKA | |
| SCHEMBL4741513 | 0.71 | TRPA1 (0.75) | TRPA1FADS1GRM4ADRA2AAURKA | |
| SCHEMBL802359 | 0.71 | TRPA1 (0.49) | TRPA1FADS1GRM4ADRA2AAURKA | |
| SCHEMBL802313 | 0.70 | TRPA1 (0.48) | TRPA1FADS1GRM4ADRA2AAURKA | |
| SCHEMBL802317 | 0.70 | FADS1 (0.48) | TRPA1FADS1GRM4ADRA2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738033-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738033-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180346451-A1 | TRK INHIBITION | NANTBIO, INC. | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346451-A1 | TRK INHIBITION | NGFR, NGF, NTRK1 | TRPA1 584/4885FADS1 3271/4885GRM4 2515/4885 |
| US-10738033-B2 | Trk inhibition | NGF, NGFR, NTRK2 | TRPA1 473/4885FADS1 3471/4885GRM4 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.